Jacob Sands, MD, Dana-Farber Cancer Institute

Articles by Jacob Sands, MD, Dana-Farber Cancer Institute

First Generation TKIs in NSCLC

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

July 8th 2021

Melissa Johnson, MD, provides an overview of other first generation TKIs for the treatment of non–small cell lung cancer (NSCLC) in the adjuvant setting.

ADAURA Trial Results and NSCLC Treatment Decisions

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

July 1st 2021

Experts discuss how results from the ADAURA trial may influence treatment decisions in the adjuvant setting of non–small cell lung cancer (NSCLC).

NSCLC: ADAURA Trial Results

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

July 1st 2021

Ben Levy, MD, leads a discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) beginning with an overview of the results from the ADAURA trial.

Jacob Sands, MD, Dana-Farber Cancer Institute

Articles by Jacob Sands, MD, Dana-Farber Cancer Institute

First Generation TKIs in NSCLC

ADAURA Trial Results and NSCLC Treatment Decisions

NSCLC: ADAURA Trial Results

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma